**Publications – Sha’ar Menashe Mental Health Center**

להלן קישורים לפרסומים אחרונים של צוות המרכז לבריאות הנפש שער מנשה

**ד"ר אלכסנדר גרינשפון**, פרופ' יובל מלמד, ד"ר יעקוב פולאקביץ, ד"ר איגור ברש, ד"ר איתן גור, ניר עמדה – הטיפול באנורקסיה נרבוזה במצב מסכן חיים – איגוד הפסיכיאטריה בישראל.  
<http://doctorsonly.co.il/wp-content/uploads/2011/11/27082012_psychiatry_Position-Paper-treatment-for-anorexia-nervosa-life-threatening-condition.pdf>

ואלרי איסק**, ; חוה קוסטיצקי , דור בר נוי , סימה מקורי .** מנהיגות בסיעוד פסיכיאטרי: בניית עתודה ניהולית. האחות בישראל, ספטמבר 2013, 36-38.

Hirschmann S, Guzner I, Lev-Ari L. The feasibility of the polygraph examination in psychotic patients. WebMed Central.

<http://www.webmedcentral.com/wmcpdf/Article_WMC004663.pdf>

Kertzman S, Avital A, Weizman A, **Segal M**. Intrusive trauma recollections is

associated with impairment of interference inhibition and psychomotor speed in

PTSD. Compr Psychiatry. 2014 May 17. [Epub ahead of print] PubMed PMID: 25023383.

<http://www.ncbi.nlm.nih.gov/pubmed/25023383>

Fogelson N, Litvak V, **Peled A**, Fernandez-Del-Olmo M, Friston K. The functional

anatomy of schizophrenia: A dynamic causal modeling study of predictive coding.

Schizophr Res. 2014 Jul 2. [Epub ahead of print] PubMed PMID: 24998031.

<http://www.ncbi.nlm.nih.gov/pubmed/24998031>

**Grinshpoon A,** Weizman A, **Amrami-Weizman A.** The Beneficial Effect of Trazodone

Treatment on Escitalopram-Associated Nocturnal Bruxism. J Clin Psychopharmacol.

2014 Jul 1. [Epub ahead of print] PubMed PMID: 24987798.

<http://www.ncbi.nlm.nih.gov/pubmed/24987798>

**Ritsner MS, Bawakny H, Kreinin A.** Pregnenolone treatment reduces severity of

negative symptoms in recent-onset schizophrenia: an 8-week, double-blind,

randomized add-on two-center trial. Psychiatry Clin Neurosci. 2014

Jun;68(6):432-40.

<http://www.ncbi.nlm.nih.gov/pubmed/24548129>

Kreinin A, **Bawakny N, Ritsner MS**. Adjunctive pregnenolone ameliorates the

cognitive deficits in recent-onset schizophrenia. Clin Schizophr Relat Psychoses.

2014 Feb 4:1-31. [Epub ahead of print] PubMed PMID: 24496044.

<http://www.ncbi.nlm.nih.gov/pubmed/24496044>

Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, **Ritsner MS**.   
The retinoid X receptor agonist bexarotene relieves positive symptoms of

schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter

trial. J Clin Psychiatry. 2013 Dec;74(12):1224-32.

<http://www.ncbi.nlm.nih.gov/pubmed/24434091>

**Ritsner MS, Lisker A, Grinshpoon A.** Predicting 10-year quality-of-life

outcomes of patients with schizophrenia and schizoaffective disorders. Psychiatry

Clin Neurosci. 2014 Apr;68(4):308-17.

<http://www.ncbi.nlm.nih.gov/pubmed/24405469>

Ponizovsky AM, Rothstein I, **Grinshpoon A.** The CANSAS self-report for screening

of needs in outpatients with schizophrenia and schizoaffective disorders.

Community Ment Health J. 2014 Apr;50(3):343-7. doi: 10.1007/s10597-013-9677-4.

Epub 2013 Dec 12. PubMed PMID: 24337474.

<http://www.ncbi.nlm.nih.gov/pubmed/24337474>

Arzouan Y, Moses E, **Peled A,** Levit-Binnun N. Impaired network stability in

schizophrenia revealed by TMS perturbations. Schizophr Res. 2014

Jan;152(1):322-4.

<http://www.ncbi.nlm.nih.gov/pubmed/24331871>

**Isakov V, Tsvelikhovsky I, Goldin V, Silver H**. What is "effective treatment"

for a schizophrenic inpatient with persistent treatment-resistant psychosis and

severe violent behavior?: a case of ECT. J ECT. 2013 Dec;29(4):e66-7

<http://www.ncbi.nlm.nih.gov/pubmed/24263278>

**Peled A.** Brain "Globalopathies" cause mental disorders. Med Hypotheses. 2013

Dec;81(6):1046-55.

<http://www.ncbi.nlm.nih.gov/pubmed/24161400>

Fogelson N, **Peled A,** Marmor S, Fernandez-del-Olmo M, Klein E. Local

contextual processing in major depressive disorder. Clin Neurophysiol. 2014

Mar;125(3):476-83.

<http://www.ncbi.nlm.nih.gov/pubmed/24076133>

**Silver H,** Bilker WB. Pathways to similar executive impairment: comparison of

schizophrenia patients and healthy aging individuals. Psychiatry Res. 2013 Dec

30;210(3):694-701.

<http://www.ncbi.nlm.nih.gov/pubmed/23972766>

**Silver H**, Bilker WB. Add-on fluvoxamine and negative symptoms of

schizophrenia: analysis of data from augmentation studies in a single center. J

Clin Psychopharmacol. 2013 Oct;33(5):710-1.

<http://www.ncbi.nlm.nih.gov/pubmed/23899641>

Fogelson N, Li L, Li Y, Fernandez-Del-Olmo M, Santos-Garcia D, **Peled A.**

Functional connectivity abnormalities during contextual processing in

schizophrenia and in Parkinson's disease. Brain Cogn. 2013 Aug;82(3):243-53.

<http://www.ncbi.nlm.nih.gov/pubmed/23721994>

Ponizovsky AM, Vitenberg E, Baumgarten-Katz I, **Grinshpoon A.** Attachment

styles and affect regulation among outpatients with schizophrenia: relationships

to symptomatology and emotional distress. Psychol Psychother. 2013

Jun;86(2):164-82.

<http://www.ncbi.nlm.nih.gov/pubmed/23674467>

**Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A**. Late onset psychosis and

risedronate treatment for osteoporosis. Clin Schizophr Relat Psychoses. 2013 May

3:1-10. <http://www.ncbi.nlm.nih.gov/pubmed/23644167>

**Ritsner MS, Mar M, Arbitman M, Grinshpoon** A. Symptom severity scale of the

DSM5 for schizophrenia, and other psychotic disorders: diagnostic validity and

clinical feasibility. Psychiatry Res. 2013 Jun 30;208(1):1-8.

<http://www.ncbi.nlm.nih.gov/pubmed/23582209>

Ritsner MS. Anhedonia of patients with schizophrenia and schizoaffective

disorder is attributed to personality-related factors rather than to

state-dependent clinical symptoms. Clin Schizophr Relat Psychoses. 2013 Mar

21:1-32. [  
<http://www.ncbi.nlm.nih.gov/pubmed/23518785>

**Ritsner MS, Grinshpoon A**. Ten-year quality of life outcomes of patients with

schizophrenia and schizoaffective disorders. Clin Schizophr Relat Psychoses. 2013

Mar 14:1-32. [  
<http://www.ncbi.nlm.nih.gov/pubmed/23491971>

**Silver H**, Einoch R, Youdim M, Weinreb O. The role of GABA-A receptor in the

synergism between SSRI and antipsychotic in schizophrenia; implications for

antipsychotic modes of actions. Curr Med Chem. 2013;20(3):363-70.

[**http://www.ncbi.nlm.nih.gov/pubmed/23157628**](http://www.ncbi.nlm.nih.gov/pubmed/23157628)

**Ritsner MS, Lisker A, Arbitman M, Grinshpoon A**. Factor structure in the Camberwell Assessment of Need-Patient Version: The correlations with dimensions of illness, personality and quality of life of schizophrenia patients. Psychiatry Clin Neurosci. 2012 Oct;66(6):499-507.

<http://www.ncbi.nlm.nih.gov/pubmed/23066767>

**Peled A.** Personality disorders disturbances of the physical brain. Med Hypotheses. 2012 Jul 23. <http://www.ncbi.nlm.nih.gov/pubmed/22832212>

**Silver H,** Goodman C, Bilker WB. Impairment in associative memory in healthy aging is distinct from that in other types of episodic memory. Psychiatry Res.2012 May 15;197(1-2):135-9. <http://www.ncbi.nlm.nih.gov/pubmed/22429482>

**Peled A.** Neuroanalysis: a method for brain-related neuroscientific diagnosis of mental disorders. Med Hypotheses. 2012 May;78(5):636-40. <http://www.ncbi.nlm.nih.gov/pubmed/22342251>

Bleich A, Baruch Y, **Hirschmann S,** Lubin G, Melamed Y, Zemishlany Z, Kaplan Z. Management of the suicidal patient in the era of defensive medicine: focus on suicide risk assessment and boundaries of responsibility. Isr Med Assoc J. 2011 Nov;13(11):653-6. <http://www.ncbi.nlm.nih.gov/pubmed/22279696>

**Grinshpoon A,** Khawaled R, Polakiewicz J, Appelbaum PS, Ponizovsky AM. Psychiatric hospitalization by court observation order in Israel: a ten year follow up study. Isr J Psychiatry Relat Sci. 2011;48(3):201-206. <http://www.ncbi.nlm.nih.gov/pubmed/22141145>

**Ritsner MS,** **Arbitman M, Lisker A**. Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 2011 Nov;199(11):845-53. <http://www.ncbi.nlm.nih.gov/pubmed/22048136>

Cloninger CR, Zohar AH, **Hirschmann S,** Dahan D. The psychological costs and benefits of being highly persistent: personality profiles distinguish mood disorders from anxiety disorders. J Affect Disord. 2012 Feb;136(3):758-66. <http://www.ncbi.nlm.nih.gov/pubmed/22036800>

Danovich L, Weinreb O, Youdim MB, **Silver H.** Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex. Psychopharmacology (Berl). 2012 Apr;220(4):763-70. <http://www.ncbi.nlm.nih.gov/pubmed/21989809>

**Ritsner MS,** **Arbitman M, Lisker A,** Ponizovsky AM. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. Qual Life Res. 2012 Aug;21(6):1075-84. <http://www.ncbi.nlm.nih.gov/pubmed/21964946>

**Ritsner MS, Lisker A, Arbitman M.** Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors. Qual Life Res. 2012 Jun;21(5):837-47. <http://www.ncbi.nlm.nih.gov/pubmed/21912845>

**Grinshpoon A,** Barchana M, Lipshitz I, Rosca P, Weizman A, Ponizovsky AM. Methadone maintenance and cancer risk: an Israeli case registry study. Drug Alcohol Depend. 2011 Dec 1;119(1-2):88-92. <http://www.ncbi.nlm.nih.gov/pubmed/21704463>

**Ritsner MS.** The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience. 2011 Sep 15;191:91-100. <http://www.ncbi.nlm.nih.gov/pubmed/21549182>

**Peled A.** Optogenetic neuronal control in schizophrenia. Med Hypotheses. 2011 Jun;76(6):914-21. <http://www.ncbi.nlm.nih.gov/pubmed/21482453>

**Ritsner MS,** Miodownik C, **Ratner Y,** Shleifer T, Mar M, Pintov L, Lerner V. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011 Jan;72(1):34-42.

<http://www.ncbi.nlm.nih.gov/pubmed/21208586>

**Silver H, Susser E**, Danovich L, Bilker W, Youdim M, **Goldin V,** Weinreb O. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. Int J Neuropsychopharmacol. 2011 Jun;14(5):573-84. <http://www.ncbi.nlm.nih.gov/pubmed/21208484>

**Grinshpoon A,** Lerner Y, Lurie TH, Zilber N, Sc D, M Ponizovsky A. Post-discharge Contact with Mental Health Clinics and Psychiatric Readmission: A 6-month Follow-up Study. Isr J Psychiatry Relat Sci. 2011;48(4):262-267. <http://www.ncbi.nlm.nih.gov/pubmed/22572089>